Janssen Biotech Inc.

11/14/2023 | Press release | Distributed by Public on 11/14/2023 06:43

New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)